To the best of our knowledge, this is the first study to use LR, SVM, and XGB fusion models by voting decision method to prospectively predict HER2 3 + and 2+/1 + expression levels in breast cancer based on a multicenter study of contrast Sonazoid-enhanced ultrasonography. This evidence concerns the gene ERBB2 and breast carcinoma.